Drug search by name

Metreleptin Subcutaneous and Obesity

Result of checking the interaction of drug Metreleptin Subcutaneous and disease Obesity for safety when used together.

Check result:

Metreleptin Subcutaneous <> Obesity

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The use of metreleptin is contraindicated in patients with general obesity not associated with congenital leptin deficiency. Metreleptin has not been shown to be effective in treating general obesity. Moreover, development of anti-metreleptin antibodies with neutralizing activity has been reported in obese patients treated with metreleptin, the clinical consequences of which have not been well characterized but could include inhibition of endogenous leptin action and loss of metreleptin efficacy. Worsening metabolic control and/or severe infection have been reported.

Metreleptin Subcutaneous

Generic Name: metreleptin

Brand Name: Myalept

Synonyms: Metreleptin

What is Metreleptin Subcutaneous?